LINDA BADDOUR
CIK 1181151 · Executive VP & CFO · last filed 2026-06-09
LINDA BADDOUR is an Executive VP & CFO who has filed 46 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for CYRX, was dated Jun 9, 2026. Across all open-market trades the lifetime net is −$44.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.16M
5
46
-$44.75M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CYRX | Director | 68,099 | $14.71 | $1.00M | $0 | 11 | 2026-06-09 |
| WAT | Director | 2,899 | $399.70 | $1.16M | -$1.09M | 13 | 2026-02-27 |
| PRA Health Sciences, Inc. (PRAH) Delisted | Executive VP & CFO | 67,000 | $165.21 | $11.07M | -$37.87M | 11 | 2018-01-18 |
| PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted | Former Chief Financial Officer | 22,057 | — | — | -$5.79M | 8 | 2008-01-25 |
| PRA International (PRAI) Delisted | EVP and CFO | — | — | — | $0 | 1 | 2007-06-06 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-09 | CYRX | Grant (A) | +10,350 | $0 | EDGAR |
| 2026-02-27 | WAT | Grant (A) | +23 | $0 | EDGAR |
| 2026-01-05 | WAT | Grant (A) | +307 | $0 | EDGAR |
| 2025-06-10 | CYRX | Grant (A) | +23,214 | $0 | EDGAR |
| 2025-01-06 | WAT | Grant (A) | +319 | $0 | EDGAR |
| 2024-05-21 | CYRX | Grant (A) | +12,845 | $0 | EDGAR |
| 2024-03-19 | CYRX | Exer (M) | +1,111 | $0 | EDGAR |
| 2024-03-14 | WAT | Sell (S) | −500 | -$177.8K | EDGAR |
| 2024-03-13 | WAT | Notice (144) | −500 | -$177.8K | EDGAR |
| 2024-01-03 | WAT | Grant (A) | +334 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.